Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis
…, O Ottmann, N Shah, P Erben, S Branford, P Agarwal… - Blood, 2007 - ashpublications.org
The prognosis for patients with chronic myeloid leukemia (CML) in myeloid blast crisis (MBC)
or lymphoid blast crisis (LBC) remains poor. Although imatinib can induce responses in a …
or lymphoid blast crisis (LBC) remains poor. Although imatinib can induce responses in a …
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase
…, D Heim, RA Larson, S Branford, MC Muller, P Agarwal… - blood, 2007 - ashpublications.org
Abstract Treatment options are limited for patients with imatinib-resistant or -intolerant
accelerated phase chronic myeloid leukemia (CML-AP). Dasatinib is a novel, potent, oral, …
accelerated phase chronic myeloid leukemia (CML-AP). Dasatinib is a novel, potent, oral, …
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind …
…, RA Subramanian, XL Xu, S Sheng, P Agarwal… - The Lancet, 2020 - thelancet.com
Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-…
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-…
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
…, AP Kollmeier, EC Hsia, XL Xu, S Sheng, P Agarwal… - The Lancet, 2020 - thelancet.com
Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic
arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 …
arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 …
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
…, C Albera, I Huizar, P Agarwal… - European …, 2014 - Eur Respiratory Soc
Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory
cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab …
cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab …
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo …
Background Sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6
cytokine with high affinity, is under development for the treatment of rheumatoid arthritis …
cytokine with high affinity, is under development for the treatment of rheumatoid arthritis …
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER …
…, EC Hsia, XL Xu, S Sheng, P Agarwal… - The Lancet …, 2021 - thelancet.com
Background Guselkumab was efficacious in reducing signs and symptoms of psoriatic arthritis
in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy …
in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy …
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
…, KF Gibson, T Haddad, P Agarwal… - European …, 2015 - Eur Respiratory Soc
The objective of this study was to determine the safety and efficacy of carlumab in the
treatment of idiopathic pulmonary fibrosis (IPF). A phase 2, randomised, double-blind placebo-…
treatment of idiopathic pulmonary fibrosis (IPF). A phase 2, randomised, double-blind placebo-…
Efficacy and safety of guselkumab, an interleukin‐23p19–specific monoclonal antibody, through one year in biologic‐naive patients with psoriatic arthritis
…, XL Xu, RA Subramanian, P Agarwal… - Arthritis & …, 2021 - Wiley Online Library
Objective Guselkumab, a human monoclonal antibody specific to interleukin‐23p19,
demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER‐2 …
demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER‐2 …
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III …
…, XL Xu, QC Zuraw, S Sheng, Y Jiang, P Agarwal… - RMD open, 2021 - rmdopen.bmj.com
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody
targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 …
targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 …